Showing 1 - 10 results of 10 for search 'Larson, R', query time: 0.03s
Refine Results
-
1
SEA-FLOOR SPREADING IN MARGINAL BASINS OF WESTERN PACIFIC by Watts, A, Weissel, J, Larson, R
Published 1977Journal article -
2
ORIGIN OF THE LOUISVILLE RIDGE AND ITS RELATIONSHIP TO THE ELTANIN FRACTURE-ZONE SYSTEM by Watts, A, Weissel, J, Duncan, R, Larson, R
Published 1988Journal article -
3
The paradox of drowned carbonate platforms and the origin of Cretaceous Pacific guyots by Wilson, P, Jenkyns, H, Elderfield, H, Larson, R
Published 1998Journal article -
4
The leukocyte integrins. by Kishimoto, T, Larson, R, Corbi, A, Dustin, M, Staunton, D, Springer, T
Published 1989Journal article -
5
Structure and regulation of the leukocyte adhesion receptor LFA-1 and its counterreceptors, ICAM-1 and ICAM-2. by Dustin, M, Garcia-Aguilar, J, Hibbs, M, Larson, R, Stacker, SA, Staunton, D, Wardlaw, A, Springer, T
Published 1989Journal article -
6
Structural insights into functional overlapping and differentiation among myosin V motors by Nascimento, A, Trindade, D, Tonoli, C, De Giuseppe, P, Assis, L, Honorato, R, Deoliveira, P, Mahajan, P, Burgess-Brown, N, von Delft, F, Larson, R, Murakami, M
Published 2013Journal article -
7
Structural insights into functional overlapping and differentiation among myosin V motors. by Nascimento, A, Trindade, D, Tonoli, C, de Giuseppe, P, Assis, L, Honorato, R, de Oliveira, P, Mahajan, P, Burgess-Brown, N, von Delft, F, Larson, R, Murakami, M
Published 2013Journal article -
8
AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML)... by Daver, N, Vyas, P, Kambhampati, S, Malki, MA, Larson, R, Asch, A, Mannis, G, Chai-Ho, W, Tanaka, T, Bradley, T, Jeyakumar, D, Wang, E, Xing, G, Chao, M, Ramsingh, G, Renard, C, Lal, I, Zeidner, J, Sallman, D
Published 2022Conference item -
9
The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results by Sallman, D, Asch, A, Kambhampati, S, Al Malki, M, Zeidner, J, Donnellan, W, Lee, D, Vyas, P, Jeyakumar, D, Mannis, G, Tanaka, T, Chai-Ho, W, Larson, R, Whiteley, A, Marcucci, G, Komrokji, R, Garcia-Manero, G, Van Elk, J, Lin, M, Maute, R, Volkmer, J-P, Takimoto, C, Chao, M, Daver, N
Published 2021Conference item -
10
A phase 3 study of Enasidenib (ENA) versus conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 (MIDH2) relapsed/refractory acute myeloid leukemia (R/R AM... by Papayannidis, C, DiNardo, C, Montesinos, P, Schuh, A, Vyas, P, Wei, A, Ommen, H, Semochkin, S, Kim, H, Larson, R, Koprivnikar, J, Frankfurt, O, Thol, F, Chromik, J, Byrne, J, Pigneux, A, Thomas, X, Salamero, O, Vidriales, M, Doronin, V, Dohner, H, Fathi, A, Laille, E, Yu, X, Hasan, M, Martin-Regueira, P, de Botton, S
Published 2021Conference item